- Neuroscientific Biopharmaceuticals is collaborating with The Institute of Respiratory Health and The University of Western Australia to evaluate the efficacy of EmtinB and other compounds as a potential treatment for post-COVID fibrosis.
- NSB would provide A$122,000 to the Institute of Respiratory Health for commencing the screening stage. The preliminary data would be available in 1H 2021.
Neuroscientific Biopharmaceuticals Limited (ASX:NSB), in partnership with The Institute of Respiratory Health and The University of Western Australia, has initiated a new preclinical program to study the effects of EmtinB and other compounds (developed from metallothionein-II) as a potential treatment for patients suffering 'post-COVID fibrosis'.
The Nedlands-headquartered pharmaceutical company specialises in the development of peptide-based pharmaceutical drugs that aim to address several neurodegenerative conditions with high unmet need.
Preclinical Program Collaboration
Through this partnership, the concerned parties would assess the efficacy of EmtinB and other metallothionein-derived peptides as a possible treatment for long term respiratory complications of Covid-19.
The Molecular Pathology Research Unit would run the preclinical program at the Institute of Respiratory Health and UWA with the help of NeuroScientific's peptide-based compounds. In this process, the Company would provide A$122,000 to the Institute of Respiratory Health for commencing the screening stage with the initial term of the research agreement agreed at four months.
The preliminary data from this new program would be available in 1H 2021.
Since its discovery in December 2019, SARS-CoV-2 has been spreading at an alarming rate with nearly 56 million cases as per the WHO (as on 19 November). With the continuous surge, it is possible that post-COVID-19 fibrosis would become one of the biggest burdens on global healthcare in the future.
Post-COVID fibrosis is irreversible and could have severe functional limitations like severe cough, shortness of breath, need for oxygen and lung transplants in a few situations. As per the latest data, pulmonary fibrosis due to COVID-19 is increasing in number with patients in the age group 20-40. The disease, as a result, is likely to create a severe global healthcare burden in the future.
A COVID-19 patient who develop Acute Respiratory Distress Syndrome (ARDS) can endure the acute phase of the illness. However, there are chances that the person might die because of progressive pulmonary fibrosis. Post-COVID fibrosis could cause long-lasting damage to the lungs, even in young adult patients.
According to recent data from independent research organisation, a natural form of EmtinB, metallothionein can protect the lungs from such injury and fibrosis.
A Glance at the Astonishing Statistics:
According to the available data, ~40% of COVID-19 patients develop ARDS, with 20% of ARDS cases falling in the severe category. Early assessment from COVID-19 patients on hospital discharge shows that over 33% of the recovered patients develop fibrotic abnormalities. Further, 47% of the patients have impaired diffusing capacity of the lungs for carbon monoxide, and 25% have reduced lungs capacity.
Stock Information: At AEDT 3:49 PM, NSB shares were trading at A$0.335, down 1.471%.
With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.